Free Shipping for orders over $49 within the U.S.

IN THE NEWS: Farlong Pharmaceutical Featured in Nutrition Insight

February 07, 2020

Lonza reopens Chinese facilities as companies wave off coronavirus threat


07 Feb 2020 --- As the coronavirus continues its spread – both within China and around the world – it is taking a serious toll on the nutrition and personal care industries as supply chains and customers feel the threat. Nonetheless, many companies remain optimistic that the epidemic will pass quickly, leaving them relatively unscathed. Lonza has resumed production at the majority of its Chinese facilities, which had remained shut earlier this week. Meanwhile, L’Oréal has acknowledged that the epidemic will have a “temporary impact” on the beauty market in China, but expects that consumption will bounce back. 


“The slightly extended shutdown of an L-Carnitine plant is not affecting customer supply as we have sufficient stock outside China to meet current demand. Going forward, we expect there to be some disruption to logistics and customs, for example, but at this stage, it is difficult to gauge the extent of potential impact. Shipments into and out of the People’s Republic of China, have been minimized due to government restrictions. Logistics are expected to begin normalizing the week of February 10, subject to local policies,” a Lonza spokesperson tells NutritionInsight

The Switzerland-based company had been investing in China, most recently with a new facility to support companies developing therapeutic proteins – from preclinical to launch phases. Currently, Lonza has four production sites in the country, one of which is still under construction. 

See full article here: